Number of patients | 185 |
Age (years) (IQR) | 68 (62−74) |
Sex (n) (male:female) | 12:173 |
Age of RA onset (years) (IQR) | 52 (43−64) |
RA disease duration (years) (IQR) | 11 (4.8−23) |
CRP level (mg/dL) (IQR) | 0.3 (0.1−1.1) |
RF positive (n) | 53 % (98/185) |
MMP3 positive (n) | 55 % (102/185) |
DAS28-CRP (IQR) | 2.3 (1.7−3.1) |
RA stage (n) | I: 10, II: 46, III: 40, IV: 89 |
Prednisolone (n) | 49 % (90/185) |
MTX (n) | 63 % (116/185) |
Biological agents (n) | 30 % (56/185) |
BMD of the lumbar spine (YAM) (IQR) | 82 % (71−93) |
BMD of the femoral neck (YAM) (IQR) | 66 % (58−66) |
Previous joint surgery (n) | 22 % (40/185) |
Administered biological agents | |
Abatacept | n = 17 |
Etanercept | n = 12 |
Infliximab | n = 10 |
Tocilizumab | n = 8 |
Certolizumab pegol | n = 5 |
Adalimumab | n = 3 |
Golimumab | n = 1 |